CN114957109B - Method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals - Google Patents
Method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals Download PDFInfo
- Publication number
- CN114957109B CN114957109B CN202210513486.3A CN202210513486A CN114957109B CN 114957109 B CN114957109 B CN 114957109B CN 202210513486 A CN202210513486 A CN 202210513486A CN 114957109 B CN114957109 B CN 114957109B
- Authority
- CN
- China
- Prior art keywords
- nicotinic acid
- temperature
- fluidity
- particle size
- acid crystals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 136
- 229960003512 nicotinic acid Drugs 0.000 title claims abstract description 72
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 71
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 71
- 239000013078 crystal Substances 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000002245 particle Substances 0.000 claims abstract description 42
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 11
- 238000001816 cooling Methods 0.000 abstract description 8
- 238000001035 drying Methods 0.000 abstract description 5
- 239000000428 dust Substances 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000009826 distribution Methods 0.000 description 15
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 238000003921 particle size analysis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 alkyl pyridine Chemical compound 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000002558 anti-leprotic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals, which is characterized in that nicotinic acid aqueous solution with the temperature of 99-102 ℃ is cooled, nicotinic acid powder with the particle size of 30-70 mu m is added, the temperature is kept for 20-30 min, cooling is carried out at a constant speed, separation is carried out by a centrifugal machine, and the agglomerated large-granularity high-fluidity nicotinic acid crystals are obtained after drying by a dryer. The nicotinic acid crystal prepared by the method has the advantages of large granularity and good fluidity, and meanwhile, dust can be reduced, so that the method is beneficial to environmental protection.
Description
Technical Field
The invention relates to a method for preparing agglomerated nicotinic acid crystals with large granularity and high fluidity.
Background
Nicotinic acid belongs to vitamin B group, also called niacin, vitamin B3, anti-leprosy factor, the molecular formula is C6H5NO2, and the chemical name is pyridine-3-formic acid. The chemical structural formula is as follows:
nicotinic acid and its derivative nicotinamide belong to vitamin B series compounds, are indispensable nutrient components in human body, and play an important role in promoting normal growth and development of human body. Nicotinic acid can influence the hematopoiesis process, promote iron absorption and hematopoiesis; maintaining normal function of the skin and secretion of digestive glands; improving the excitability of central nerve and the functions of cardiovascular system, reticuloendothelial system and endocrine. In addition, the production performance of livestock and poultry can be improved. Nicotinic acid can significantly improve feed conversion rate and laying rate, and when insufficient, affects glycolysis, citric acid circulation, respiratory chain and fatty acid biosynthesis, thereby causing nicotinic acid deficiency.
Nicotinic acid is also an important pharmaceutical raw material and chemical intermediate. The nicotinic acid can be used for synthesizing a plurality of medicaments for treating various skin diseases, hypertension, coronary heart disease and the like, and can also be used as medicament intermediates for producing isoniazid, nikkimei and inositol nicotinate. Nicotinic acid is also widely used in luminescent materials, dyes, animal feeds, etc.
At present, nicotinic acid mainly comprises two synthetic methods, namely an alkyl pyridine direct oxidation method and a cyanopyridine hydrolysis method, the existing industrial production mainly comprises an ammoxidation method and a biosynthesis method in the cyanopyridine hydrolysis method, the appearance of the prepared product is white crystal or white crystalline powder, the average particle size is only 50-150 mu m, the product has poor fluidity, the nicotinic acid is not easy to mix with other auxiliary materials when being used, dust is large when being fed, allergic reaction is easily caused by sticking to skin or respiratory tract, and the problems of small granularity, poor fluidity and large dust are not solved in the product produced by the existing crystallization granulation method.
Disclosure of Invention
The invention provides a method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals, which solves the technical problems that the prepared nicotinic acid product is agglomerated crystal particles, the average particle size of the particles is large, the product is similar to a sphere, the fluidity of the product is good, the dust is less during feeding, and the use is convenient.
In order to solve the technical problems, the invention adopts the following technical scheme:
a process for preparing the agglomerated high-granularity high-flowability nicotinic acid crystal includes such steps as cooling the aqueous solution of nicotinic acid at 99-102 deg.C, adding the nicotinic acid powder with 30-70 microns in granularity, thermal insulating for 20-30 min, cooling at constant speed at 55-65 r/min, centrifugal separation, and drying.
The mass concentration of the nicotinic acid in the nicotinic acid aqueous solution is 9% -11%.
The addition amount of the nicotinic acid powder is 1-3% of the mass of the nicotinic acid aqueous solution.
The nicotinic acid aqueous solution is cooled down to the temperature of 95-98 ℃.
The temperature is reduced to 20-30 ℃ at a constant rate.
The constant rate is 0.5 ℃/min.
The invention has the following beneficial technical effects:
according to the preparation method, the nicotinic acid powder with the particle size of 30-70 mu m is added after cooling, the nicotinic acid powder is kept for a period of time, and the prepared nicotinic acid product is agglomerated crystal particles through cooling at a constant rate, so that the average particle size of the particles is large, the product is similar to a sphere, the fluidity is good, the dust is less during feeding, and the use is convenient.
Drawings
FIG. 1 is a microscopic image of niacin crystals produced in example 1;
FIG. 2 is a microscopic image of niacin crystals produced in example 2;
FIG. 3 is a microscopic image of niacin crystals produced in example 3;
FIG. 4 is a crystal microscopic image of niacin of comparative example 1;
FIG. 5 is a crystal microscopic image of niacin of comparative example 2;
FIG. 6 is a graph showing the particle size distribution of nicotinic acid crystals prepared in example 1;
FIG. 7 is a graph showing the particle size distribution of nicotinic acid crystals prepared in example 2;
FIG. 8 is a graph showing the particle size distribution of nicotinic acid crystals prepared in example 3;
FIG. 9 is a graph showing the particle size distribution of nicotinic acid crystals prepared in comparative example 1;
FIG. 10 is a graph showing the particle size distribution of nicotinic acid crystals prepared in comparative example 2.
Detailed Description
The invention will be further illustrated with reference to specific examples.
Example 1
In a 50L crystallization kettle, 40L of nicotinic acid aqueous solution is prepared according to the mass concentration of 10%, the temperature is raised to 101 ℃, the stirring rotation speed is controlled to be 60r/min, the temperature is kept for 30 minutes under the condition, the temperature is slowly reduced to 98 ℃, then 50g of prepared nicotinic acid powder with the average particle size of 39.4 mu m is added as seed crystal, the stability is carried out for 22 minutes, then the temperature is reduced at the cooling rate of 0.5 ℃/min, and the temperature of the solution is reduced to 25 ℃, so that the crystallization is completed. And (3) carrying out solid-liquid separation on the solution by using a centrifugal machine to obtain agglomerated nicotinic acid crystal particles, and then drying the nicotinic acid particles by using a dryer to obtain the agglomerated nicotinic acid crystal particles. The product was subjected to particle size analysis using a Markov particle sizer to determine that the product had a particle size distribution Dv (50) of 296 μm.
The particle size distribution results are shown in the following table:
| project | Dv（10）（um） | Dv（50）（um） | Dv（90）（um） | Bottom cumulative result 50um% |
| Results | 120 | 296 | 495 | 3.99 |
The result of the test on the bulk density of nicotinic acid crystals was 0.57g/mL.
Example 2
In a 50L crystallization kettle, 40L of nicotinic acid aqueous solution is prepared according to the mass concentration of 9.8%, the temperature is raised to 100 ℃, the stirring rotation speed is controlled to be 60r/min, the temperature is kept for 30 minutes under the condition, the temperature is slowly reduced to 96 ℃, then 60g of prepared nicotinic acid powder with the average particle size of 50 mu m is added as seed crystal, the stability is carried out for 25 minutes, then the temperature is reduced at the cooling rate of 0.5 ℃/min, and the temperature of the solution is reduced to 25 ℃, so that the crystallization is completed. And (3) carrying out solid-liquid separation on the solution by using a centrifugal machine to obtain agglomerated nicotinic acid crystal particles, and then drying the nicotinic acid particles by using a dryer to obtain the agglomerated nicotinic acid crystal particles.
The product was subjected to particle size analysis using a Markov particle sizer to determine that the product had a particle size distribution Dv (50) of 283 μm.
The particle size distribution results are shown in the following table:
| project | Dv（10）（um） | Dv（50）（um） | Dv（90）（um） | Bottom cumulative result 50um% |
| Results | 90.8 | 283 | 552 | 5.10 |
The test result of the bulk density of the nicotinic acid crystals is 0.55g/mL.
Example 3
In a 50L crystallization kettle, 40L of nicotinic acid aqueous solution is prepared according to the mass concentration of 10.5%, the temperature is raised to 102 ℃, the stirring rotation speed is controlled to be 60r/min, the temperature is kept for 30 minutes under the condition, the temperature is slowly reduced to 98 ℃, then 80g of prepared nicotinic acid powder with the average particle size of 50 mu m is added as seed crystal, the stability is carried out for 22 minutes, then the temperature is reduced at the cooling rate of 0.5 ℃/min, and the temperature of the solution is reduced to 26 ℃, so that the crystallization is completed. And (3) carrying out solid-liquid separation on the solution by using a centrifugal machine to obtain agglomerated nicotinic acid crystal particles, and then drying the nicotinic acid particles by using a dryer to obtain the agglomerated nicotinic acid crystal particles. The product was subjected to particle size analysis using a Markov particle sizer to determine that the product had a particle size distribution Dv (50) of 286 μm.
The particle size distribution results are shown in the following table:
| project | Dv（10）（um） | Dv（50）（um） | Dv（90）（um） | Bottom cumulative result 50um% |
| Results | 91.8 | 286 | 545 | 5.06 |
The detection result of the obtained nicotinic acid crystal bulk density is 0.59g/mL
Comparative example 1
The particle size distribution Dv (50) of the commercially available niacin product from company a was determined to be 31.1 μm using a malvern particle sizer.
The particle size distribution results are shown in the following table:
| project | Dv（10）（um） | Dv（50）（um） | Dv（90）（um） | Bottom cumulative result 50um% |
| Results | 7.65 | 31.1 | 266 | 60.92 |
Comparative example 2
The particle size distribution Dv (50) of the commercially available niacin product from company B was determined to be 31.1 μm using a malvern particle sizer.
The particle size distribution results are shown in the following table:
| project | Dv（10）（um） | Dv（50）（um） | Dv（90）（um） | Bottom cumulative result 50um% |
| Results | 32.1 | 157 | 421 | 16.01 |
Claims (2)
1. A method for preparing nicotinic acid crystals is characterized in that a nicotinic acid aqueous solution with the temperature of 99-102 ℃ is cooled to the temperature of 95-98 ℃, nicotinic acid powder with the particle size of 30-70 mu m is added, the addition amount of the nicotinic acid powder is 1-3% of the mass of the nicotinic acid aqueous solution, the temperature is kept for 20-30 min, the temperature is cooled to the temperature of 20-30 ℃ at a constant speed of 0.5 ℃/min under the condition of the rotating speed of 55-65 r/min, and the nicotinic acid crystals are separated by a centrifugal machine and dried by a dryer, so that the agglomerated high-granularity high-fluidity nicotinic acid crystals are obtained.
2. A method for preparing nicotinic acid crystals as claimed in claim 1, wherein the mass concentration of nicotinic acid in the aqueous solution of nicotinic acid is 9-11%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210513486.3A CN114957109B (en) | 2022-05-12 | 2022-05-12 | Method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210513486.3A CN114957109B (en) | 2022-05-12 | 2022-05-12 | Method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114957109A CN114957109A (en) | 2022-08-30 |
| CN114957109B true CN114957109B (en) | 2024-03-08 |
Family
ID=82981355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210513486.3A Active CN114957109B (en) | 2022-05-12 | 2022-05-12 | Method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114957109B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113717097B (en) * | 2021-10-21 | 2024-01-12 | 河北工业大学 | Method for preparing nicotinic acid crystals with large granularity and high bulk density and without coalescence |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101565401A (en) * | 2009-06-01 | 2009-10-28 | 杭州胜大药业有限公司 | Granular niacin production method by extrusion and granulation |
| CN102295599A (en) * | 2011-06-09 | 2011-12-28 | 许万根 | Production method and granulation method for nicotinic acid |
| CN105646339A (en) * | 2015-12-30 | 2016-06-08 | 西安航天华威化工生物工程有限公司 | Method for preparing nicotinic acid by low-temperature reaction crystallization |
| CN107382844A (en) * | 2017-08-28 | 2017-11-24 | 天津科技大学 | A kind of method that nicotinic acid is produced using niacinamide usp as raw material |
| CN108997206A (en) * | 2018-09-19 | 2018-12-14 | 安徽瑞邦生物科技有限公司 | A method of niacin is produced by raw material of Ammonium nicotinate |
| CN113717097A (en) * | 2021-10-21 | 2021-11-30 | 河北工业大学 | Method for preparing large-particle-size high-bulk-density non-agglomeration nicotinic acid crystals |
-
2022
- 2022-05-12 CN CN202210513486.3A patent/CN114957109B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101565401A (en) * | 2009-06-01 | 2009-10-28 | 杭州胜大药业有限公司 | Granular niacin production method by extrusion and granulation |
| CN102295599A (en) * | 2011-06-09 | 2011-12-28 | 许万根 | Production method and granulation method for nicotinic acid |
| CN105646339A (en) * | 2015-12-30 | 2016-06-08 | 西安航天华威化工生物工程有限公司 | Method for preparing nicotinic acid by low-temperature reaction crystallization |
| CN107382844A (en) * | 2017-08-28 | 2017-11-24 | 天津科技大学 | A kind of method that nicotinic acid is produced using niacinamide usp as raw material |
| CN108997206A (en) * | 2018-09-19 | 2018-12-14 | 安徽瑞邦生物科技有限公司 | A method of niacin is produced by raw material of Ammonium nicotinate |
| CN113717097A (en) * | 2021-10-21 | 2021-11-30 | 河北工业大学 | Method for preparing large-particle-size high-bulk-density non-agglomeration nicotinic acid crystals |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114957109A (en) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114957109B (en) | Method for preparing agglomerated large-granularity high-fluidity nicotinic acid crystals | |
| EP0593896B1 (en) | RS-thioctic acid with a new morphology | |
| DE10244397A1 (en) | Choline formulations | |
| CN104788472B (en) | One water Cefazolin sodium spheroidal particle and its crystallization preparation method | |
| CN113185456B (en) | Method for refining nicotinic acid | |
| TW201217311A (en) | Process for the production of L-carnitine tartrate | |
| JP2016520037A (en) | Reduced coenzyme Q10 powder, composition thereof and production method | |
| CN114651898B (en) | Triazole feed additive for improving immunity as well as preparation method and application thereof | |
| CN109232389B (en) | Method for preparing small-particle-size nifedipine crystals | |
| CN110559265A (en) | preparation method of acetyl L-carnitine arginine dihydrochloride moisture-proof particles | |
| JP3623531B2 (en) | Process for producing crystalline L-ascorbic acid-2-phosphate magnesium salt | |
| CN102212564A (en) | Fermentation method for producing gamma-aminobutyric acid and fermentation culture medium thereof | |
| CN110526879B (en) | Crystallization preparation method of small-granularity febuxostat | |
| JPH02200693A (en) | Production of high-purity lactulose powder and production of bifidus bacteria preparation containing lactulose | |
| CN105777595B (en) | A kind of Fudosteine preparation method of suitable industrialized production | |
| CN104761463B (en) | D pantothenic acid sodium crystal and its production and use | |
| EP0345591A1 (en) | Propanol amine derivatives | |
| TWI693209B (en) | Method for preparing sacubitril sodium salt and application thereof | |
| US11981642B1 (en) | 4-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)butanoic acid as an antimicrobial compound | |
| US11970460B1 (en) | 4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound | |
| CN103509072A (en) | Preparation method of micro-powder capecitabine | |
| US11976046B1 (en) | 4-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound | |
| CN114052126A (en) | Rumen-bypass coated product containing (1,2,5, 6-O-selenium) -D-ganoderic acid glucose and preparation method thereof | |
| CN114621083A (en) | Antihistamine medicine fexofenadine hydrochloride impurity and synthesis method and application thereof | |
| CN108794391B (en) | Novel nicotinic acid medicinal salt and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |